Treatment of T2DM with vildagliptin for 8 weeks decreased significantly the serum small dense LDL levels by about 9% and the urinary albumin-to-creatinine ratio (UACR) by about 45%, suggesting that vildagliptin might prevent cardiovascular disease by improving LDL heterogeneity and improve renal function by decreasing albuminuria. Here, ALB is linked to cardiovascular disorder.